2026 Chinese Expert Consensus on Remission of Type 2 Diabetes (English Version)

Full title: Chinese Expert Consensus on Remission of Type 2 Diabetes (2026), issued by the Chinese Diabetes Society (CDS), published in Diabetes Care or Chinese Journal of Endocrinology and Metabolism (English edition), 2026 Core positioning: First national Chinese consensus specifically for T2DM remission. Defines remission as HbA1c < 6.5% without antihyperglycemic agents for ≥3 months. Eligibility limited to short-duration T2DM (usually < 10 years), preserved β-cell function, obesity/overweight. Strategy: structured low-energy diet + lifestyle intervention first; GLP-1 RAs as adjunct; metabolic surgery for severe obesity. Emphasizes that remission ≠ cure; lifelong monitoring required. Complements ACLM 2026 lifestyle medicine guideline, ACP 2026 obesity pharmacotherapy, EASO/EFAD/ECPO incretin nutrition consensus.

1. Definition and Stages of Remission

Core definition (CDS 2026)

T2DM remission: HbA1c < 6.5% (48 mmol/mol) maintained for ≥3 months without any glucose-lowering medication (oral antidiabetic drugs or insulin).

• Partial remission: HbA1c 5.7–6.4%, off meds ≥3 months;
• Complete remission: HbA1c < 5.7%, off meds ≥3 months;
• Sustained remission: off meds ≥12 months.

Key: HbA1c measured at 3-month intervals; single normal value not sufficient. CGM/GMI can support but not replace HbA1c.

Important caveat

Remission does not mean cure. β-cell function continues to decline; weight regain and aging can lead to re-emergence of hyperglycemia.

2. Eligibility Criteria

✅ Candidates most likely to achieve remission

1. Diabetes duration < 10 years (best < 5 years);
2. Preserved endogenous insulin secretion: fasting C-peptide ≥ 1.1 ng/mL (≥0.33 nmol/L), stimulated C-peptide ≥ 2.5 ng/mL;
3. Overweight/obesity: BMI ≥ 24 kg/m² (Chinese cut-off), especially BMI ≥ 28;
4. No insulin dependence, no history of ketoacidosis;
5. No advanced complications (ESRD, advanced CVD, severe retinopathy);
6. Motivated, able to adhere to intensive lifestyle intervention.

❌ Not suitable for remission attempt

• Long-standing T2DM (>10 years) with severe β-cell failure;
• Insulin-dependent T2DM, history of DKA;
• Type 1 diabetes, LADA;
• Severe malnutrition, active eating disorder;
• Advanced complications limiting intervention.

3. Remission Strategies (Tiered Approach)

Tier 1: Intensive lifestyle intervention (first-line)

1. Low-energy diet (LED): 800–1000 kcal/day for 8–12 weeks under medical supervision; then gradual reintroduction of solid food;
2. Protein: 1.2–1.5 g/kg body weight/day, preserve lean mass;
3. Physical activity: 150 min/week moderate aerobic + resistance training 2–3 times/week;
4. Behavioral support: regular follow-up, self-monitoring, psychological support.

Target: weight loss ≥ 10% in 3–6 months; every 1% weight loss increases remission probability.

Tier 2: GLP-1 receptor agonist adjunct

• For patients who cannot achieve sufficient weight loss with lifestyle alone, or have inadequate glycemic control;
• Semaglutide (subcutaneous, escalating to 2.4 mg weekly) or liraglutide;
• Can be combined with LED for greater weight loss;
• Monitor gastrointestinal tolerance, gallbladder function.

Tier 3: Metabolic bariatric surgery

• BMI ≥ 32.5 kg/m² (Chinese criteria), or BMI ≥ 27.5 with T2DM inadequately controlled despite medical therapy;
• Sleeve gastrectomy or RYGB;
• Highest remission rate (up to 60–80% in suitable candidates);
• Requires bariatric center MDT (cross-reference ASMBS 2026 post-surgery weight recurrence statement).

4. Monitoring and Tapering of Medications

1. Baseline: HbA1c, fasting/postprandial glucose, C-peptide, lipid panel, liver function, body weight, waist circumference;
2. During active weight loss phase (first 3–6 months):
   • Frequent glucose monitoring (CGM recommended for insulin users);
   • Sulfonylureas and insulin should be tapered/stopped proactively to prevent hypoglycemia as weight drops;
   • Metformin can be continued or stopped based on glycemic status;
   • GLP-1 RA continued as long as tolerated;
3. After 3–6 months: recheck HbA1c; if < 6.5% off glucose-lowering meds for 3 months → remission achieved;
4. If HbA1c ≥ 6.5%: adjust therapy, do not force remission.

5. Maintenance After Remission

1. Continue healthy lifestyle: weight maintenance ± 2–3 kg;
2. Monitor HbA1c every 3 months for first year, then every 6 months;
3. Monitor weight monthly; weight regain > 3 kg triggers lifestyle re-intensification;
4. Annual screening for complications (eye, kidney, foot, cardiovascular);
5. GLP-1 RA may be continued long-term to maintain weight; stopping GLP-1 without lifestyle maintenance leads to weight regain and relapse.

6. Special Populations

1. Elderly (≥65 years): remission attempt only if biologically fit, short duration, preserved C-peptide; prioritize safety over aggressive weight loss;
2. Pregnancy/planning: remission should be maintained pre-conception; pregnancy requires obstetric + endocrinology co-management (cross-reference ADA 2026 pregnancy guideline);
3. CKD: LED requires protein adjustment; GLP-1 RA safe if eGFR ≥ 15;
4. MASH/fatty liver: remission improves liver histology (cross-reference 2026 UK BASL/BSG MASH consensus);
5. Gestational diabetes history: future T2DM risk; lifestyle intervention for prevention.

7. Common Pitfalls

❌ Attempting remission in long-duration, insulin-dependent T2DM; ❌ Stopping insulin abruptly without glucose monitoring; ❌ Using very-low-calorie diets without medical supervision; ❌ Assuming remission means permanent cure; abandoning follow-up; ❌ Forgetting to monitor for complications after remission.

8. Evidence Gaps

1. Long-term (10-year) remission durability in Chinese population;
2. Optimal duration of GLP-1 RA maintenance after remission;
3. Genetic/biomarker predictors of remission in Chinese T2DM patients;
4. Comparison of LED vs GLP-1 vs surgery in Chinese population.

9. Cross-reference with Prior Guideline Series

1. This 2026 Chinese T2DM Remission Consensus: national framework for T2DM remission in Chinese adults;
2. ACLM 2026 Lifestyle Medicine Guideline: lifestyle as first-line for T2DM treatment and remission;
3. ACP 2026 Obesity Pharmacotherapy Guideline: GLP-1 RA as first-line obesity drug in primary care;
4. EASO/EFAD/ECPO 2026 Incretin Consensus: nutritional and psychological support during incretin therapy;
5. ASMBS 2026 Post-bariatric Weight Recurrence: metabolic surgery as remission option, post-surgery maintenance.

Disclaimer: This summary is for academic study only. T2DM remission attempt requires endocrinology MDT evaluation, close glucose monitoring, and structured follow-up. Medication tapering must be supervised to avoid hypoglycemia